Geron Corp

NASDAQ: GERN
$4.25
-$0.04 (-0.9%)
Closing Price on November 8, 2024

GERN Stock Chart and Intraday Price

GERN Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 149 COMMONWEALTH DRIVE, SUITE 2070, MENLO PARK, CA, US
Fiscal Year End December
Latest Quarter 9/30/2023
Market Cap 1,227.33M USD
Shares Outstanding 543,064,000
Geron Corp is a biopharmaceutical company focused on developing treatments for blood cancers. Its main project, imetelstat, is a groundbreaking therapy aimed at stopping the spread of cancerous cells in certain blood disorders. This innovative drug is currently in advanced testing stages, showing promise for patients with specific types of myelodysplastic syndromes and myelofibrosis. Founded in 1990 and based in Foster City, California, Geron is at the forefront of research in telomerase inhibition, a novel approach in cancer treatment.

GERN Articles

Monday's top analyst upgrades and downgrades included Amazon.com, Canopy Growth, CarMax, Chipotle Mexican Grill, Geron, Hess, Inogen, Occidental Petroleum, Snap, Teva Pharmaceutical, Vail Resorts and...
The top analyst upgrades, downgrades and initiations for Tuesday included Annaly Capital Management, Amazon.com, Enterprise Products Partners, Kinder Morgan, Lululemon Athletica, RealReal, Snap,...
The top analyst upgrades, downgrades and initiations seen on Tuesday included Anadarko Petroleum, Apple, Charter Communications, Geron, KLA-Tencor, PVH, SAP, Walt Disney and United States Steel.
The top analyst upgrades, downgrades and initiations seen on Wednesday included Activision Blizzard, Biogen, Deere, DocuSign, Ford, Freeport-McMoRan, General Motors, Lattice Semiconductor, Qualys,...
Judging by the most shorted stocks traded on the Nasdaq between the September 14 and September 28 settlement dates, those sellers were looking for direction.
Geron, Ford, Conagra, and Bed, Bath & Beyond all posted new 52-week lows Thursday.
Geron shares were absolutely crushed on Thursday morning after it was announced that Janssen Biotech has terminated the 2014 collaboration and license agreement with the firm.
Judging by the most shorted stocks traded on the Nasdaq between the August 31 and September 14 settlement dates, those sellers were focused on Qualcomm.
Judging by the most shorted stocks traded on the Nasdaq between the August 15 and August 31 settlement dates, those sellers may have been looking for direction.
Judging by the most shorted stocks traded on the Nasdaq between the July 31 and August 15 settlement dates, those sellers were focused on one favorite -- Caesars Entertainment.
Judging by the most shorted stocks traded on the Nasdaq between the July 31 and August 15 settlement dates, those sellers were focused on one favorite -- Caesars Entertainment.
Judging by the most shorted stocks traded on the Nasdaq between the July 13 and July 31 settlement dates, those sellers were looking for direction, as moves in their favorites were mixed and modest.
Judging by the most shorted stocks traded on the Nasdaq between the June 29 and July 13 settlement dates, those sellers were cautious, as their favorites saw shrinking or flat short interest.
Judging by the most shorted stocks traded on the Nasdaq between the June 15 and June 29 settlement dates, those sellers were focused on a few of favorites.
The top analyst upgrades, downgrades and other research calls from Thursday include Allergan, Cheniere Energy, Clean Energy, Facebook, Fiat Chrysler, Intel and NetApp.